A. Adler · I. Yaniv · Z. Samra · J. Yacobovich ·
S. Fisher · G. Avrahami · I. Levy

***Exserohilum*: an emerging human pathogen**

Published online: 5 April 2006
© Springer-Verlag 2006

Eur J Clin Microbiol Infect Dis (2006) This issue

Due to a typesetting error, the last column was omitted from Tables 1 and 2.

The complete and correct Tables 1 and 2 appear here.

The online version of the original article can be found at:
<http://dx.doi.org/10.1007/s10096-006-0093-3>.

A. Adler · I. Levy
Unit of Pediatric Infectious Diseases and Hospital Infection
Control, Schneider Children's Medical Center of Israel,
14 Kaplan Street,
P.O. Box 559 Petah Tiqva, 49202, Israel

I. Yaniv · J. Yacobovich · S. Fisher · G. Avrahami
Department of Pediatric Hematology–Oncology and Unit of
Hematopoietic Stem Cell Transplantation,
Schneider Children's Medical Center of Israel,
14 Kaplan Street,
P.O. Box 559 Petah Tiqva, 49202, Israel

Z. Samra
Microbiology Department, Rabin Medical Center,
Beilinson Campus, 14 Kaplan Street,
P.O. Box 559 Petah Tiqva, 49202, Israel

A. Adler · I. Yaniv · Z. Samra · J. Yacobovich · S. Fisher ·
G. Avrahami · I. Levy
Sackler Faculty of Medicine, Tel Aviv University,
Tel Aviv, Israel

A. Adler (✉)
Department of Clinical Microbiology and Infectious Diseases,
Hadassah Medical Center,
Kiryat Hadassah, Ein Karem,
Jerusalem, Israel
e-mail: amosa@hadassah.org.il
Tel.: +972-2-6776543
Fax: +972-2-6419545

Table 1 Characteristics of patients with invasive *Exserohilum* infection

Patient no. [ref.]	Age (y)/ sex	<i>Exserohilum</i> species	Country/ year of report	Underlying disease and predisposing factors	Sites of infection	Therapy (antifungal susceptibility; duration)	Outcome
1 [5]	12/ M	<i>rostratum</i> ^a	Western USA/1980	None	Bone	Surgery, local and systemic AmB ^c	Cure
2 [6]	20/ F	<i>longirostratum</i> ^b	France/1983	Surgical correction of congenital VSD and AI	Endocarditis, vertebral osteomyelitis	AmB, keto (72 h MFC= 1 µg/ml for both; 10 months), surgery	Cure
3 [7]	63/ M	<i>rostratum</i>	Israel/1987	AML; antimicrobial and chemotherapy; neutropenia	Skin (cutaneous), nasal mucosa	AmB (2 months)	Cure
4 [8]	5/ F	<i>rostratum</i>	Texas, USA/1990	Aplastic anemia; cytotoxic therapy	Paranasal sinuses, soft tissue	AmB (48 h MIC< 0.14 µg/ml), itra (48 h MIC<0.02 µg/ml)	Progression; death due to bacterial sepsis
5 [9]	16/ M	NR	South Africa/1993	None	Skin (subcutaneous), lung, brain	AmB (total dose 2.5 g), 5-flu	Cure
6 [10]	7/ F	<i>rostratum</i>	Texas, USA/1994	Aplastic anemia	Paranasal sinuses, lungs	AmB	Death
7 [11]	41/ F	NR	Israel/2004	AML	Paranasal sinuses, lungs	AmB, itra	Failure; death due to bacterial sepsis
8 [12]	8/ M	NR	Israel/2003	ALL, antimicrobial and chemotherapy; neutropenia	Skin (cutaneous), Paranasal sinuses, lungs	AmB, itra (5 mos.)	Cure; death due to malignancy and <i>Fusarium</i> infection
9 [PR]	8/ F	NR	Israel/2005	ALL; antimicrobial and chemotherapy; neutropenia	Paranasal sinuses, lungs	AmB, vori (9 months), surgery	Cure
10 [PR]	3/ F	NR	Israel/2005	ALL; antimicrobial and chemotherapy; neutropenia	Paranasal sinuses, soft palate	AmB, itra (13 months), surgery	Cure

PR present report, VSD ventricular septal defect, AI aortic insufficiency, AmB amphotericin B, keto ketoconazole, MFC minimum fungicidal concentration, 5-flu 5-flucytosine, AML acute myelogenous leukemia, MIC, minimum inhibitory concentration, itra itraconazole, ALL acute lymphoblastic leukemia, vori voriconazole, NR not reported

^aIsolate originally reported as *Drechslera rostrata*

^bIsolate originally reported as *Drechslera longirostrata*

^cTherapy was required intermittently for frequent recurrences of the infection up to 8 years after presentation

Table 2 Characteristics of patients with *Exserohilum* skin and corneal infections

Patient no. [ref.]	Age (y)/ sex	<i>Exserohilum</i> species	Country/year of report	Underlying diseases and predisposing factors	Sites of infection	Therapy (antifungal susceptibility; duration)	Outcome
11 [3]	34/F	<i>rostratum</i>	Calif., USA/1986	Cardiac transplantation; immunosuppression	Skin (subcutaneous)	AmB, keto, surgery	Cure
12 [13]	55/F	<i>rostratum</i>	S. Carolina, USA/1987	Fish sting	Skin (subcutaneous)	Surgery, keto (6 weeks)	Cure
13 [14]	3/M	<i>rostratum</i>	Tenn., USA/1991	ALL; antimicrobial and chemotherapy; neutropenia; local cloth tape	Skin (cutaneous)	AmB (24 h MIC=0.39 µg/ml; 1 month), 5-flu (24 h MIC >20 µg/ml; 2 weeks)	Cure
14 [15]	74/M	<i>rostratum</i>	Texas, USA/1991	COPD; steroid therapy	Skin (cutaneous)	Keto+topical clotrimazole (6 weeks)	Cure
15 [16]	63/M	<i>rostratum</i>	Taiwan/1993	Diabetes; local trauma	Skin (subcutaneous)	Keto (3 weeks)	No improvement; death due to bacterial sepsis
16 [16]	31/M	<i>rostratum</i>	Taiwan/1993	Topical steroids for psoriasis	Skin (cutaneous)	Topical bifonazole (2 weeks)	Cure
17 [17]	22/M	<i>rostratum</i>	Va., USA/1993	Superficial lacerations; cocaine use, MOF	Skin (cutaneous)	AmB	Death due to MOF
18 [18]	40/F	<i>rostratum</i>	India/1995	None	Skin (cutaneous)	None	Unknown
19 [19]	NR/ NR	<i>rostratum</i> ^a	Fla., USA/1975	None	Cornea	Topical gentamicin	Cure
20 [20]	40/F	<i>rostratum</i>	India/1991	Rt. eye injury from a paddy leaf	Cornea	Topical keto	No improvement
21 [21]	47/M	<i>longirostratum</i>	Honduras/1994	Left eye struck by unknown foreign body during train riding	Cornea and uvea	Surgery, keto	Cure following enucleation
22 [22]	55/M	<i>rostratum</i>	India/1996	Lash injury to rt. eye by cow's tail	Cornea	Topical nata + mico (6 weeks)	Cure (vision 6/18)
23 [23]	42/M	<i>rostratum</i>	India/1999	None	Cornea	Surgery, topical keto+nata	Cure (vision 6/18)
24 [24]	18/F	<i>rostratum</i>	India/2004	None	Cornea	topical itra	Cure

AmB, amphotericin B, keto ketoconazole, MIC minimum inhibitory concentration, ALL acute lymphoblastic leukemia, 5-flu 5-flucytosine, COPD chronic obstructive pulmonary disease, MOF multiorgan failure, mico miconazole, NR not reported

^aIsolate originally reported as *Drechslera halodes*